Investors should monitor the upcoming 16-week data readout for ORKA-001 in 2Q 2026 as a key catalyst; the accelerated timeline may signal strong trial performance and could positively impact sentiment if results are robust.
ORKA drugs
ORKA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 13 $40.00entry
- T+1 · 8mo ago +4.38%α +3.35% · $41.75
- T+5 · 8mo ago −2.73%α −0.61% · $38.91
- T+20 · 7mo ago +53.45%α +49.86% · $61.38
- T+60 · 5mo ago +60.15%α +48.54% · $64.06
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Oruka Therapeutics reported fourth quarter and full year 2025 financial results, highlighted by $479.6 million in cash and advancement of its two lead programs: ORKA-001 and ORKA-002. Enrollment in the EVERLAST-A trial for ORKA-001 completed ahead of schedule, with 16-week data now expected in 2Q 2026. The Phase 2 ORCA-SURGE trial for ORKA-002 in psoriasis has been initiated, with data anticipated in 2027.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and marketable securities totaled $479.6 million as of December 31, 2025.
- Net loss was $29.6 million in Q4 2025 and $105.4 million for the full year 2025.
- R&D expenses were $27.6 million in Q4 2025 and $100.6 million for the full year 2025.
- Enrollment in EVERLAST-A (ORKA-001) completed in December 2025; 16-week data expected in 2Q 2026.
- ORCA-SURGE Phase 2 trial for ORKA-002 in psoriasis initiated in February 2026, with data expected in 2027.
Financial Impact
Increased R&D and G&A spending led to higher net loss in 2025 vs. prior period, but strong cash position supports continued development.
Risk Factors
- Clinical development risk: Data from ORKA-001 and ORKA-002 may not meet efficacy or safety expectations.
- Dilution risk: Future capital raises may be necessary beyond 2027, depending on burn rate and development costs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255109 |
Track record
40 reports on ORKA
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 11 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers